Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Ovarian Epithelial × Topotecan × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 8 Ovarian Neoplasms 5 Neuroblastoma 5 Uterine Cervical Neoplasms 3 Neoplasms 3 Ganglioneuroblastoma 3 Sarcoma, Ewing 2 Fallopian Tube Neoplasms 2 Brain Neoplasms 2 Wilms Tumor 1 Thrombocythemia, Essential 1 Rhabdoid Tumor 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Pleuropulmonary blastoma 1 Osteosarcoma 1 Myelodysplastic-Myeloproliferative Diseases 1 Medulloblastoma 1 Lymphoma, Follicular 1 Localized Extraskeletal Ewing Sarcoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Glioma 1 Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 5 Bevacizumab 5 Carboplatin 4 mirvetuximab soravtansine 3 pembrolizumab 2 olaparib 2 liposomal doxorubicin 2 Hyperthermic Intraperitoneal Chemotherapy 2 trastuzumab deruxtecan 1 rucaparib 1 ribociclib 1 pegfilgrastim 1 palbociclib 1 niraparib 1 isoquercitrin 1 fludarabine phosphate 1 fludarabine 1 cemiplimab 1 Topotecan 1 Saline Solution 1 Preoperative Exercise 1 Platinum 1 Pharmaceutical Preparations 1 Nutrition Assessment 1 Nivolumab 1 Neoadjuvant Therapy 1 Injections 1 Immunotherapy, Adoptive 1 Glucose 1 GEN-1 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07218809 2026-01-16

TREVI-OC-01

AstraZeneca

Phase 3 Recruiting

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡